Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Elucidating the molecular mechanisms of age-related muscle loss to inform Artificial Intelligence-based discovery of novel peptide therapeutics for sarcopenia.

Project description

A novel in vitro model of age-related muscle loss

Age-related muscle atrophy is a condition that affects millions of individuals worldwide decreasing both quality of life and life expectancy. Existing experimental models do not account for the role of cellular ageing and senescence in muscle wasting, resulting in the design of ineffective therapies. To address this problem, the EU-funded Pept-AGE project will develop an improved in vitro model that effectively recapitulates age-related muscle loss and use it to identify the affected pathways. By integrating results from the in vitro model into Nuritas' Artificial intelligence peptide finder platform, deep learning will further contribute to the discovery of novel bioactive peptides capable of ameliorating muscle loss. The clinically relevant Pept-AGE model has the potential to advance therapeutics against disorders associated with muscle atrophy.

Objective

Loss of muscle function through advancing age, injury or disease significantly decreases both the quality of life and life expectancy of millions of individuals globally. Treatments tackling this issue have proven elusive as in vitro systems aimed at modelling age-related muscle atrophy are primarily murine based and fail to capture the complexity of this process in humans. In particular, these models neglect to accurately account for the impact of cellular-ageing and senescence on the advancement of sarcopenia-induced muscle wastage. This project aims to address these problems by firstly developing a more human aligned in vitro ageing model to elucidate key pathways associated with muscle loss. From this in vitro model, we will identify key mechanistic pathways driving age-related muscle loss at the transcriptional and translational level. Supplied with suitable data, artificial intelligence (AI) has to potential to rapidly accelerate the discovery of novel therapeutics. As such, here, informed by data derived from the human in vitro model, Nuritas’ proven artificial intelligence platform will be applied to identify novel bioactive peptides that have the potential to counter the impact of cellular aging thus ameliorating muscle loss. This innovative proposal affords the experienced researcher the opportunity to bring his knowledge at the forefront of ageing research back to Europe and combine it with the expertise of an industry leader in AI therapeutic discovery, facilitating decisive two-way intersectoral transfer of knowledge. By integrating these distinct interdisciplinary skillsets this project has the expected outcomes of discovering more clinically relevant, translational models and therapeutics for muscle wastage disorders.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

NURITAS LIMITED
Net EU contribution
€ 196 590,72
Address
JOSHUA DAWSON HOUSE, 19B DAWSON STREET
D02 RY95 Dublin 2
Ireland
SME
Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 196 590,72